Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -25.78% is 74% below its 1-year average of -14.83%, near the low end of its 1-year range (-25.78%–-8.37%).
As of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -25.78%.
RETURN ON EQUITY (ROE)
-25.78%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 525 covered companies
CURRENT VS SECTOR MEDIAN
+35.87%
vs the sector median at left
LB Pharmaceuticals Inc Common Stock
Market Cap
$976.44M
Return on Equity (ROE)
-25.78%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$978.88M
Return on Equity (ROE)
36.64%
TTM Avg
876.73%
3Y Avg
395.64%
5Y Avg
252.56%
Market Cap
$986.73M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$987.45M
Return on Equity (ROE)
-15.09%
TTM Avg
46.85%
3Y Avg
62.20%
5Y Avg
62.20%
Market Cap
$998.92M
Return on Equity (ROE)
-11.06%
TTM Avg
-9.32%
3Y Avg
-13.81%
5Y Avg
-2.96%
Market Cap
$1.01B
Return on Equity (ROE)
-52.47%
TTM Avg
-18.98%
3Y Avg
-16.96%
5Y Avg
-116.25%
Market Cap
$1.01B
Return on Equity (ROE)
-63.62%
TTM Avg
-41.08%
3Y Avg
-23.78%
5Y Avg
-22.76%
Market Cap
$1.01B
Return on Equity (ROE)
-0.69%
TTM Avg
-24.98%
3Y Avg
-8.92%
5Y Avg
-2.80%
Market Cap
$1.02B
Return on Equity (ROE)
-4.51%
TTM Avg
-33.13%
3Y Avg
-42.62%
5Y Avg
-42.62%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $976.44M | -25.78% | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $978.88M | 36.64% | 876.73% | 395.64% | 252.56% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $986.73M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $987.45M | -15.09% | 46.85% | 62.20% | 62.20% |
| Janux Therapeutics, Inc. (JANX)vs › | $998.92M | -11.06% | -9.32% | -13.81% | -2.96% |
| Immatics N.V. (IMTX)vs › | $1.01B | -52.47% | -18.98% | -16.96% | -116.25% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | -63.62% | -41.08% | -23.78% | -22.76% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.01B | -0.69% | -24.98% | -8.92% | -2.80% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | -4.51% | -33.13% | -42.62% | -42.62% |
| CeriBell, Inc. (CBLL)vs › | $931.87M | -51.43% | -27.77% | 3.43% | 3.43% |
ROE
-25.8%
ROA
-23.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -25.78% |
| 2026-03-31 | -10.34% |
| 2025-12-31 | -8.37% |
